Centogene - CNTG Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Centogene in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CNTG shares.
View CNTG analyst ratings or view top-rated stocks.

3 equities research analysts have issued 1-year price targets for Centogene's stock. Their CNTG share price forecasts range from $2.50 to $6.00. On average, they anticipate the company's stock price to reach $4.25 in the next twelve months. This suggests a possible upside of 418.3% from the stock's current price.
View analysts price targets for CNTG or view top-rated stocks among Wall Street analysts.

Centogene's stock was trading at $5.2283 at the beginning of 2022. Since then, CNTG stock has decreased by 84.3% and is now trading at $0.82.
View the best growth stocks for 2022 here.

Centogene saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 32,500 shares, an increase of 19.0% from the October 31st total of 27,300 shares. Based on an average trading volume of 16,800 shares, the days-to-cover ratio is presently 1.9 days. Currently, 0.5% of the company's shares are short sold.
View Centogene's Short Interest.

Centogene (NASDAQ:CNTG) posted its quarterly earnings results on Wednesday, November, 24th. The company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by $0.49. The firm had revenue of $35.60 million for the quarter, compared to analyst estimates of $31.91 million. Centogene had a negative net margin of 35.35% and a negative trailing twelve-month return on equity of 134.55%. During the same period in the prior year, the business posted ($0.32) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Centogene investors own include Fulcrum Therapeutics (FULC), Advanced Micro Devices (AMD), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Alimera Sciences (ALIM), AngloGold Ashanti (AU), Chimerix (CMRX) and Entasis Therapeutics (ETTX).

(CNTG) raised $60 million in an IPO on Thursday, November 7th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. SVB Leerink and Evercore ISI acted as the underwriters for the IPO and Baird and BTIG were co-managers.

Centogene trades on the NASDAQ under the ticker symbol "CNTG."

Centogene's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Platinum Investment Management Ltd. (8.78%).

Shares of CNTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CNTG stock can currently be purchased for approximately $0.82.

Centogene (NASDAQ:CNTG) has a market capitalization of $22.21 million and generates $224.71 million in revenue each year. The company earns $-55,430,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis.

The company employs 660 workers across the globe.

Centogene's mailing address is AM STRANDE 7, ROSTOCK 2M, 18055. The official website for the company is www.centogene.com. The company can be reached via phone at 38180113500 or via email at investor.relations@centogene.com.